135 related articles for article (PubMed ID: 22516666)
1. Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic.
Diaper A; Osman-Hicks V; Rich AS; Craig K; Dourish CT; Dawson GR; Nutt DJ; Bailey JE
J Psychopharmacol; 2013 Feb; 27(2):135-45. PubMed ID: 22516666
[TBL] [Abstract][Full Text] [Related]
2. Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate.
Diaper A; Rich AS; Wilson SJ; Craig K; Dourish CT; Dawson GR; Nutt DJ; Bailey JE
Hum Psychopharmacol; 2013 Nov; 28(6):562-75. PubMed ID: 23955418
[TBL] [Abstract][Full Text] [Related]
3. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
Baldwin DS; Schweizer E; Xu Y; Lyndon G
Eur Neuropsychopharmacol; 2012 Feb; 22(2):137-42. PubMed ID: 21839620
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety.
Bailey JE; Papadopoulos A; Seddon K; Nutt DJ
J Psychopharmacol; 2009 Mar; 23(2):117-22. PubMed ID: 18562427
[TBL] [Abstract][Full Text] [Related]
5. The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures.
Papadopoulos A; Rich A; Nutt DJ; Bailey JE
J Psychopharmacol; 2010 May; 24(5):649-56. PubMed ID: 18832434
[TBL] [Abstract][Full Text] [Related]
6. The effect of a clinically effective and non-effective dose of lorazepam on 7.5% CO₂-induced anxiety.
Diaper A; Papadopoulos A; Rich AS; Dawson GR; Dourish CT; Nutt DJ; Bailey JE
Hum Psychopharmacol; 2012 Nov; 27(6):540-8. PubMed ID: 23027657
[TBL] [Abstract][Full Text] [Related]
7. Effects of 7.5% CO2 challenge in generalized anxiety disorder.
Seddon K; Morris K; Bailey J; Potokar J; Rich A; Wilson S; Bettica P; Nutt DJ
J Psychopharmacol; 2011 Jan; 25(1):43-51. PubMed ID: 20233897
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety.
Bailey JE; Papadopoulos A; Diaper A; Phillips S; Schmidt M; van der Ark P; Dourish CT; Dawson GR; Nutt DJ
J Psychopharmacol; 2011 Sep; 25(9):1199-206. PubMed ID: 21555331
[TBL] [Abstract][Full Text] [Related]
9. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study.
Feltner DE; Liu-Dumaw M; Schweizer E; Bielski R
Int Clin Psychopharmacol; 2011 Jul; 26(4):213-20. PubMed ID: 21368587
[TBL] [Abstract][Full Text] [Related]
11. Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers.
Bailey JE; Argyropoulos SV; Kendrick AH; Nutt DJ
Depress Anxiety; 2005; 21(1):18-25. PubMed ID: 15782425
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder.
Feltner DE; Crockatt JG; Dubovsky SJ; Cohn CK; Shrivastava RK; Targum SD; Liu-Dumaw M; Carter CM; Pande AC
J Clin Psychopharmacol; 2003 Jun; 23(3):240-9. PubMed ID: 12826986
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
[TBL] [Abstract][Full Text] [Related]
14. A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers.
Bailey JE; Kendrick A; Diaper A; Potokar JP; Nutt DJ
J Psychopharmacol; 2007 Jan; 21(1):42-9. PubMed ID: 16533865
[TBL] [Abstract][Full Text] [Related]
15. Oxytocin interference in the effects induced by inhalation of 7.5% CO(2) in healthy volunteers.
de Oliveira DC; Chagas MH; Garcia LV; Crippa JA; Zuardi AW
Hum Psychopharmacol; 2012 Jul; 27(4):378-85. PubMed ID: 22711428
[TBL] [Abstract][Full Text] [Related]
16. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention.
Bandelow B; Wedekind D; Leon T
Expert Rev Neurother; 2007 Jul; 7(7):769-81. PubMed ID: 17610384
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
[TBL] [Abstract][Full Text] [Related]
18. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study.
Pollack MH; Worthington JJ; Otto MW; Maki KM; Smoller JW; Manfro GG; Rudolph R; Rosenbaum JF
Psychopharmacol Bull; 1996; 32(4):667-70. PubMed ID: 8993089
[TBL] [Abstract][Full Text] [Related]
19. The effects of 7.5% carbon dioxide inhalation on task performance in healthy volunteers.
Diaper A; Nutt DJ; Munafò MR; White JL; Farmer EW; Bailey JE
J Psychopharmacol; 2012 Apr; 26(4):487-96. PubMed ID: 21890588
[TBL] [Abstract][Full Text] [Related]
20. Venlafaxine and generalised anxiety disorder: new preparation. Minimise recourse to drugs.
Prescrire Int; 2001 Oct; 10(55):131-4. PubMed ID: 11824426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
